^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OriC321

    i
    Other names: OriC321, BMCA and GPRC5D dual target CAR-T cells
    Associations

    News

    Trials
    Company:
    Zhejiang University
    Drug class:
    BCMA-targeted CAR-T immunotherapy, GPRC5D-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2years
    A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Zhejiang University
    New P1 trial • CAR T-Cell Therapy
    |
    GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    BM-ca • OriC321